Genmab
GMAB
Performance
About Genmab
Genmab is an international biotechnology company focused on creating and developing antibody therapeutics to treat cancer and other serious diseases. The company emphasizes pioneering antibody science and proprietary technologies to advance next-generation medicines, with a global presence including regional sites in Japan and the United States. Genmab emphasizes collaborations with healthcare professionals, patients, and partners to transform patient outcomes and drive innovation in oncology and related fields. Its mission includes incorporating patient perspectives and sustainable practices across its research, development, and corporate activities.
Recent News
Analysis Finds Efficiencies, Savings of Using a Single Bispecific for DLBCL and FL
FDA Revises Recommendation on First Full Epcoritamab Dose in R/R DLBCL to Allow Outpatient Monitoring
Anthropic: It’s “Critical” To Bring Company Products to EHR
Seven Biotech Companies to Know in the Netherlands
AbbVie, Genmab’s Bispecific Misses Key Overall Survival Endpoint in Phase III Lymphoma Study
J&J Builds Case for Earlier Tecvayli Use in Multiple Myeloma
Bone Disease Readout Sinks Mereo, Ultragenyx Shares: Clinical Roundup
Three Undervalued Growth Stocks the Market Has Missed
Genmab Halts Enrollment for Cancer Drug From ProfoundBio Buyout
AbbVie, Genmab Say Epkinly Didn't Prolong Overall Survival in Lymphoma Study
Recent Deals
No recent deals for this company.
